Glaxosmithkline LS-,25

GS7

(XETRA)

€ 20,48 <%= Resources.Global.txtUp %>

Opdateret 24-05-2013
ISIN: GB0009252882

Ændring %	1,01%
Ændring	0,21
Volume	14.953
Høj	€ 20,48
Lav	€ 20,15
Åben	€ 20,39

Seneste luk	€ 20,27
# af aktier	-
Markedsværdi	-

Idag

Market closed

Marked er lukket, åbner klokken 09:00


Kursudvikling	Seneste	1 uge	1 måned	3 mdr	6 mdr	1 år

	20,48	1,1%	1,9%	21,5%	22,7%	15,6%

Dansk
Engelsk
Fondsbørsmeddelelser

	22 maj	U.S. Gives Glaxo Up To $200 Million for Antibiotic Research

	22 maj	GlaxoSmithKline Awarded Up to $200 Million by US to Develop New Antibiotics

	22 maj	GlaxoSmithKline Shuts Australia Packaging Site

	22 maj	GlaxoSmithKline Shuts Australian Tablet-Packing Site

	14 maj	2ND UPDATE: C.R. Bard to Pay $48.3 Million to Settle Kickback Case -DOJ

	13 maj	LONDON MARKETS: GSK, Shell Lead U.K. Stocks To 8th Day Of Gains

	13 maj	LONDON MARKETS: GSK, Shell Lead U.K. Stocks To 8th Day Of Gains

	13 maj	EUROPE MARKETS: Europe Stocks Retreat From 2013 High

	13 maj	Elan Signs $1 Billion Drug Deal

	13 maj	Elan, Theravance Enter Into $1.0 Billion Royalty Participation Pact

Flere nyheder

GlaxoSmithKline (GSK) is a global pharmaceutical company with the majority of sales coming from pharmaceuticals followed by consumer healthcare. Most of the growth for GSK is coming from consumer healthcare because of declining pharmaceutical sales and margins from mature markets. The sector is highly dependent on expensive, long term R&D to develop new drugs. To establish a stronger brand presence in China and India, the company has aggressively cut prices to increase volumes in these markets.

Glaxosmithkline LS-,25

For lav Flash Player version

Nyheder om Glaxosmithkline LS-,25

Firma profil